---
document_datetime: 2024-02-12 11:43:36
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/all-authorised-presentations/tecentriq-epar-all-authorised-presentations_en.pdf
document_name: tecentriq-epar-all-authorised-presentations_en.pdf
version: success
processing_time: 0.8669417
conversion_datetime: 2025-12-22 07:21:36.187961
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
| MA (EU) number   | (Invented) name   | Strength   | Pharmaceutical Form                   | Route of Administration   | Immediate Packaging   | Content (concentration)   | Pack size   |
|------------------|-------------------|------------|---------------------------------------|---------------------------|-----------------------|---------------------------|-------------|
| EU/1/17/1220/001 | Tecentriq         | 1200 mg    | Concentrate for solution for infusion | Intravenous use           | vial (glass)          | 20 ml (60 mg/ml)          | 1 vial      |
| EU/1/17/1220/002 | Tecentriq         | 840 mg     | Concentrate for solution for infusion | Intravenous use           | vial (glass)          | 14 ml (60 mg/ml)          | 1 vial      |
| EU/1/17/1220/003 | Tecentriq         | 1875 mg    | Solution for injection                | Subcutaneous use          | vial (glass)          | 15 ml (125 mg/ml)         | 1 vial      |